Longevity Report


This report is based on your raw file genome’s data cross-referencing against available genetic databases and constructing a report based on interpretations in these databases. Variant annotations were made with OakVar. Annotation databases that was used for report generating: cadd_exome, gnomAD, pubmed, clinpred, clinvar, ncbigene, omim, prec, provean, revel, sift, LongevityMap.

Attention! The information provided is just for informational purposes. Its clinical implementation is possible just after consulting your healthcare practitioner. All drugs, vitamins and lifestyle changes may be prescribed just by your healthcare practitioner, based on clinical blood test results, family history etc. Genetical testing just provides additional information about possible health risk and risk management.

The report consists of:

Longevity variants

This report estimates how many significant longevity variations you have and whether its "a lot" or "not so" for your population. The data for this report is obtained mainly by studying centenarians’ genomes.

The longevity variants report is based on 1900 variants from LongevityMap ( genomics.senescence.info/longevity ) and other data sources which are scored and prioritized according to multiple criteria. It also depends on ClinGene, dbSNP and ClinVar modules.

In the table you can see, how many significant for your population variants were found in your genome. Positively longevity-associated variants are marked with green, negatively associated - with red.

We have analyzed genes that affect different longevity pathways in your genome. We have divided them according to the longevity pathways they contribute to. So you can see which of them “work well” and which do not so.

Longevity pathways encompass a fascinating realm of biological processes and signaling pathways that play a crucial role in regulating aging and lifespan. Recent advancements in our understanding of these pathways have yielded valuable insights, including the identification of specific genes that impact the aging process [PMID:33891896].

To help you better understand the role your genes play in longevity, we have categorized them into 11 distinct groups.

Our analysis has allowed us to identify which of your genes contribute to different longevity pathways, giving you a clearer picture of which genes are performing well and which ones may need additional attention.

There is data on Polygenic risk scores (PRSs) for gaining longevity.

PRSs aggregate the effect of many common genetic variants to estimate a person’s chances of gaining extreme longevity. Each variant on its own tends little to the total outcome, but when added together, these differences can have a more significant impact.

PRS results are highly dependent on the population. PPS is calculated as a weighted sum of trait-associated alleles. PRS gives an estimate of how likely an individual is to have a given trait only based on genetics, without taking environmental factors into account.

How to read the result?

PRS is represented as a percentile within a given population. For example, you have the 95th percentile, which means your genetic chances to gain extreme longevity is higher than 95 out of every 100 people in a chosen population.

So percentile >50 shows an increased genetic predisposition to longevity, <50 - decreased one.

PRS info

This PRS includes an analysis of 332 variants that significantly discriminated between centenarians and older adults.

PRS source: https://doi.org/10.1093/gerona/glaa289

TitleLongevity PRS (PRS5)
Sum6.147905555255802
Count/total114/332
Average0.02696449804936755
Percentile94%

Lipids play crucial roles in regulating aging and longevity. Lipids are key biological molecules that contribute to cellular and organismal functions in three principal ways. First, they are fundamental structural elements of cellular membranes. Second, they are key molecules in energy metabolism to fuel the cell. Third, they play roles by acting as signaling molecules. Lipid metabolism is not considered a separate longevity pathway, but genes that regulate lipid transfer, like APOE and CETP, show the strongest association with longevity. This is a list of genes we analyzed in your genotype related to lipid transfer:

+
RSIDPopulationGene Your genotypeRef alleleAlt alleleZygosity Weight
+
rs429358multiple APOE C/TTChet-0.5
+
rs4420638multiple APOC1 G/AAGhet-0.375
+
rs405509Danish, German, Dutch APOE G/GTGhom-0.3
+
rs4784744Danish, German, Dutch CETP A/GGAhet0.05
+
rs7524519American (Caucasian) LYPLAL1 G/AAGhet0.07
+
rs9916344American (Caucasian) PITPNM3 T/CCThet0.07
+
rs289714Danish, German, Dutch CETP A/GGAhet0.15
+
rs1800774Danish, German, Dutch CETP T/CCThet0.15
+
rs440446Danish, German, Dutch APOE G/GCGhom0.3

From 9 gene variants involved in lipid metabolism and longevity pathways, you have 6 favorable and 3 unfavorable.


If your genetic testing reveals that you have unfavorable forms of genes involved in lipid and cholesterol transfer, there are several things you can do to manage your risk and improve your health:

Monitor your health: Regular check-ups and monitoring of your cholesterol levels, blood pressure, and other health parameters can help to identify any issues early and allow for prompt intervention.

Biochemical markers for check-ups: Triglycerides, Total cholesterol level, LDL and HDL cholesterol, and the atherogenicity index (AI). It is a good idea to monitor these markers on a regular basis, at least once per year.

Adopt a healthy lifestyle: it sounds not innovative, but getting regular exercise and maintaining a healthy weight can help to lower your risk of unfavorable lipid metabolism genes.

Take medications if recommended: Your healthcare professional may recommend medications such as statins, which can help to lower your cholesterol levels and reduce your risk of developing cardiovascular disease. Do not take any medicaments if they are not prescribed by a doctor.

Look at pharmacogenetics: If your biochemical lipid profile is disturbed, consider that variations in these genes may be associated with differences in response to statin therapy.

The insulin/insulin-like growth factor (IGF-1) signaling pathway is a key regulator of metabolism, growth, and aging. It has been extensively studied in various model organisms, including worms, flies, and mice, and is also thought to play an important role in human aging and longevity. This pathway is also involved in glucose metabolism. This is a list of genes we analyzed in your genotype related to insulin/IGF-1 signaling pathway:

+
RSIDPopulationGene Your genotypeRef alleleAlt alleleZygosity Weight
+
rs2267723Danish GHRHR G/AAGhet-0.11
+
rs5771675American (Caucasian) FAM19A5 G/AAGhet0.065
+
rs3842755Danish INS A/CCAhet0.11
+
rs216493American (Caucasian) PLEKHA7 G/GAGhom0.14
+
rs155979Korean PCSK1 C/CGChom0.14
+
rs768023German A/GGAhet0.175
+
rs572169Danish GHSR T/TCThom0.22
+
rs6911407German A/CCAhet0.25
+
rs4946936Chinese (Han) FOXO3 C/TTChet0.25
+
rs2802290German FOXO3 A/GGAhet0.3
+
rs473268German A/CCAhet0.35
+
rs479744multiple multiple T/GGThet0.395
+
rs9400239multiple FOXO3 C/TTChet0.435
+
rs7762395multiple FOXO3 A/GGAhet0.445
+
rs13217795multiple FOXO3 T/CCThet0.46

From 15 gene variants involved in insulin/IGF-1 signaling pathways, you have 14 favorable and 1 unfavorable.


If you have unfavorable variants of insulin/IGF-1 signaling pathway genes, there are several lifestyle changes you can make to help promote healthy aging and reduce the risk of age-related diseases:

Diet: A healthy, balanced diet that is low in sugar and processed foods can help to regulate insulin and IGF-1 levels, which may help to mitigate the effects of unfavorable genes.

Exercise: Regular exercise has been shown to improve insulin sensitivity and promote healthy aging. Aim for at least 30 minutes of moderate-intensity exercise most days of the week, such as brisk walking, cycling, or swimming.

Stress management: Chronic stress can contribute to insulin resistance and age-related diseases. Incorporating stress-management techniques such as meditation, yoga, or deep breathing into your daily routine can help to reduce stress and promote healthy aging.

Sleep: Poor sleep has been linked to insulin resistance and other age-related diseases. Aim for at least 7-8 hours of sleep each night and establish a regular sleep routine to support healthy aging.

Biochemical markers for check-ups: insulin, fasting glucose level, Hemoglobin A1c (HbA1c), and C-peptide. It is a good idea to monitor these markers on a regular basis, at least once per year.

Antioxidant defense plays an important role in the aging process and longevity. Oxidative stress, which is caused by an imbalance between the production of reactive oxygen species (ROS) and the body's ability to neutralize them, is a major contributor to age-related diseases and the aging process.

The body has various mechanisms to defend against oxidative stress, including antioxidant enzymes such as superoxide dismutase (SOD), catalase, and glutathione peroxidase, as well as non-enzymatic antioxidants such as vitamins C and E, and glutathione. These antioxidants work together to neutralize ROS and prevent damage to cells and tissues.

Studies have shown that increased antioxidant defense can promote longevity and delay the onset of age-related diseases. This is a list of genes we analyzed in your genotype related to antioxidant defense:

+
RSIDPopulationGene Your genotypeRef alleleAlt alleleZygosity Weight
+
rs7319813American (Caucasian) ENOX1 T/CCThet0.07
+
rs4964735Danish TXNRD1 A/GGAhet0.105
+
rs7301631Danish TXNRD1 C/TTChet0.105
+
rs17202060Danish TXNRD1 T/CCThet0.105
+
rs7962759Danish TXNRD1 G/CCGhet0.105
+
rs7318601American (Caucasian) ENOX1 A/AGAhom0.14
+
rs10861169Danish TXNRD1 T/TCThom0.21
+
rs4964728Danish TXNRD1 A/AGAhom0.21
+
rs7310505Danish TXNRD1 C/CAChom0.21
+
rs10778318Danish TXNRD1 G/GAGhom0.21

From 10 gene variants involved in antioxidant defense, you have 10 favorable and 0 unfavorable.

If you have unfavorable variants of antioxidant system genes, there are several lifestyle changes you can make to help promote healthy aging and reduce the risk of age-related diseases:

Ensure the uptake of all components needed for your antioxidant system works appropriately:

Glutathione (which is an important component of your defense) is composed of the amino acids glutamate, cysteine, and glycine. Its’ synthesis requires magnesium, zinc, selenium, and vitamins B2, B6, and B12 as cofactors. Ensure you take all these components from food. NAC supplementation can be used to boost glutathione synthesis.

Flavonoids: They are a group of plant compounds that have antioxidant and anti-inflammatory properties. Good food sources of flavonoids include berries, apples, citrus fruits, and tea.

Selenium: It is a mineral that is important for the production of antioxidant enzymes in the body. Good food sources of selenium include Brazil nuts, seafood, and organ meats.

Polyphenols are a group of naturally occurring compounds found in plant-based foods, including fruits, vegetables, nuts, seeds, and grains. They are known to have antioxidant properties, which means they can help protect the body against damage caused by free radicals.

Polyphenols work by neutralizing free radicals and preventing them from causing oxidative damage to cells and tissues. They can also boost the activity of the body's own antioxidant enzymes, including glutathione peroxidase and superoxide dismutase.Some of the most commonly studied polyphenols include resveratrol, found in grapes and red wine, catechins, found in green tea, and quercetin, found in onions, apples, and berries. Other sources of polyphenols include cocoa, dark chocolate, coffee, and many types of fruits and vegetables.

Biochemical markers for a check-up: oxidized low-density lipoprotein (oxLDL), Fe/Cu ratio, glutathione, 8-hydroxy-2’-deoxyguanosine (8-OHdG) (a marker of oxidative damage to DNA), malondialdehyde (MDA) (it is a byproduct of lipid peroxidation and is used as a marker of oxidative stress). It is a good idea to monitor these markers on a regular basis, at least once per year.

Mitochondria are the powerhouses of the cell, generating the energy (in the form of ATP) needed for cellular processes. They also play a key role in apoptosis (programmed cell death) and other cellular processes. Mitochondrial dysfunction and increased oxidative stress are believed to play a role in the aging process and age-related diseases. Several genes involved in mitochondrial function have been implicated in longevity. They include UCP genes, genes involved in respiratory chain functioning, SIRT3, PGC1a, and some other genes.

In general, the form of these genes determines how well you are protected from oxidative stress and how effectively your cells generate energy. This is a list of genes we analyzed in your genotype related to mitochondria function:

+
RSIDPopulationGene Your genotypeRef alleleAlt alleleZygosity Weight
+
rs6435326Danish NDUFS1 T/TAThom-0.19
+
rs9557276American (Caucasian) CLYBL T/TGThom0.14
+
rs3019435American (Caucasian) PRKN T/TGThom0.14
+
rs1042718Chinese ADRB2 A/ACAhom0.195
+
rs1042719Chinese ADRB2 C/CGChom0.195
+
rs15763Italian (Southern) UCP3 G/AAGhet0.245
+
rs6435324Danish NDUFS1 G/GAGhom0.38

From 7 gene variants involved in mitochondrial function, you have 6 favorable and 1 unfavorable.


If you have unfavorable variants in genes involved in mitochondrial function, there are several steps you can take to improve your health outcomes potentially:


Biochemical markers for check-ups: lactate, pyruvate, and creatine kinase, markers of oxidative stress, such as glutathione level and Fe/Cu ratio.

Consider adequate uptake of trace elements and vitamins essential for mitochondria function: magnesium, B vitamins (particularly thiamine (B1), riboflavin (B2), and niacin (B3)), selenium, iron, copper, and vitamin E.

Exercise: Regular exercise has been shown to increase mitochondrial biogenesis (the process of creating new mitochondria) and improve mitochondrial function. This is thought to be due to increased energy demand during exercise, which triggers the body to produce more mitochondria.

The sirtuin genes (SIRT1-SIRT7) are a family of genes that are involved in regulating cellular processes such as DNA repair, metabolism, and stress response. The sirtuin pathway, which involves the activity of these genes, has been implicated in regulating longevity.

Studies have shown that activation of sirtuins can increase lifespan in several model organisms, including yeast, worms, and mice. This is thought to be due to the role of sirtuins in promoting cellular resilience and protecting cells from damage.

In humans, variations in the SIRT genes have been associated with age-related diseases such as Alzheimer's disease, cardiovascular disease, and cancer. Some studies have also suggested that increased activity of SIRT genes may be associated with increased lifespan and improved healthspan in humans.

This is a list of genes we analyzed in your genotype related to sirtuin pathway:

+
RSIDPopulationGene Your genotypeRef alleleAlt alleleZygosity Weight
+
rs107251Danish, German, Dutch SIRT6 C/TTChet0.15

From 1 gene variants involved in the sirtuin pathway, you have 1 favorable and 0 unfavorable.


There are several ways to activate the sirtuin pathway if your genes are not favorable:


Exercise: Exercise has been shown to increase sirtuin activity in multiple tissues, including skeletal muscle, liver, and brain. Both endurance and resistance exercise may be effective in activating the sirtuin pathway.

Supplementation: Supplementation with compounds such as resveratrol and nicotinamide riboside has been shown to increase sirtuin activity in multiple tissues. These compounds are thought to work by mimicking the effects of caloric restriction on sirtuin activity. Consider that in human trials effect of these compounds has not yet been shown. So before taking any supplements, consult your healthcare practitioner.

Intermittent fasting: Intermittent fasting is a dietary strategy that involves cycling between periods of fasting and non-fasting. Intermittent fasting has been shown to increase sirtuin activity in multiple tissues and may activate the sirtuin pathway.

MTOR, also known as the mechanistic target of rapamycin, is a gene that encodes for a protein kinase involved in multiple cellular processes, including growth, metabolism, and aging. The mTOR pathway plays a complex role in aging and longevity. On the one hand, activation of the mTOR pathway has been shown to promote cellular growth and proliferation, which may be beneficial for tissue repair and regeneration during early life stages. On the other hand, chronic activation of the mTOR pathway has been implicated in age-related diseases such as cancer, metabolic disorders, and neurodegeneration.

Studies have shown that genetic or pharmacological inhibition of the mTOR pathway can extend the lifespan in a variety of model organisms, including mice, flies, and worms. Additionally, modulation of the mTOR pathway has been shown to improve age-related functional decline and delay the onset of age-related diseases in various animal models.

Genetic variants in the MTOR gene may be associated with differences in lifespan and age-related disease risk.

+
RSIDPopulationGene Your genotypeRef alleleAlt alleleZygosity Weight
+
rs1016339American (Caucasian) CCDC85A T/CCThet0.07
+
rs4729049American (Caucasian) CDK6 C/TTChet0.07
+
rs10937739American (Caucasian) PPP2R2C C/TTChet0.08

From 3 gene variants involved in mTOR pathway, you have 3 favorable and 0 unfavorable.


There are several ways to influence mTOR pathway if your genes are not favorable:


Fasting: Intermittent fasting or periodic fasting has been shown to decrease mTOR activity.

Use spices: Curcumin is a compound found in turmeric, which has been shown to inhibit mTOR activity.

Plant-based diet: A diet rich in fruits, vegetables, whole grains, and legumes has been associated with decreased mTOR activity.

Tumor suppressor genes and cell cycle regulators are not typically considered as "longevity genes" per se, but they do play an important role in the aging process and the development of age-related diseases, including cancer.

One well-known tumor suppressor gene is TP53, which has been shown to play a role in regulating cellular senescence and preventing the accumulation of damaged cells. Similarly, cell cycle regulators such as cyclin-dependent kinases (CDKs) are involved in regulating the timing and progression of cell division. The dysregulation of CDKs has been implicated in a variety of age-related diseases, including cancer and neurodegenerative disorders.

+
RSIDPopulationGene Your genotypeRef alleleAlt alleleZygosity Weight
+
rs4977756American (Caucasian) CDKN2B-AS1 A/GGAhet-0.18
+
rs1063192American (Caucasian) CDKN2B A/GGAhet0.18
+
rs1412832American (Caucasian) CDKN2B-AS1 T/CCThet0.18
+
rs3120819American (Caucasian) TP53 C/AAChet0.24
+
rs13008689American (Caucasian) TP53 A/GGAhet0.24
+
rs9616906American (Caucasian) TP53 A/GGAhet0.24
+
rs10819510American (Caucasian) TP53 G/AAGhet0.24
+
rs189037multiple ATM A/GGAhet0.33

From 8 gene variants of tumor-suppressive genes, you have 7 favorable and 1 unfavorable regarding their impact on longevity*.


If you have unfavorable variants in genes involved in genome maintenance, there are several steps you can take to improve your health outcomes potentially:


Ensure methylation processes in your body work well: monitor blood levels of B12, B9, B2, B6, Zn, and Co[PMID: 31601260, PMID: 36203899]. These components are needed for methylation enzymes' appropriate work. Methylation is important for genome maintenance because it is involved in the regulation of gene expression and DNA repair [PMID: 34209979].

Reduce exposure to environmental toxins, such as pollution, pesticides, and chemicals. Air-control indoor systems can help with this point.

Protect the skin from UV radiation by wearing protective clothing and using sunscreen.

Avoid tobacco: Tobacco use is a leading cause of cancer, so avoiding tobacco in all forms, including smoking, vaping, and chewing, can significantly decrease the risk of cancer.

*In our analysis, we have categorized tumor-suppressive gene variants based solely on their effect on longevity as either favorable or unfavorable. We would like to clarify that our report does not provide an assessment of whether these variants have an increased risk for cancer or not.

The renin-angiotensin system (RAS) plays an important role in the regulation of blood pressure, fluid balance, and electrolyte homeostasis. However, it is also involved in the aging process and the development of age-related diseases.

One of the mechanisms by which RAS influences aging is through the activation of oxidative stress and inflammation. RAS also affects the cardiovascular system and is involved in the development of hypertension, a major risk factor for cardiovascular diseases such as heart attack and stroke. Furthermore, RAS activation has been linked to the development of insulin resistance and metabolic syndrome, which are also associated with aging and age-related diseases.

In addition, RAS has been implicated in the regulation of cellular senescence, a process by which cells lose their ability to divide and contribute to aging and age-related diseases.

+
RSIDPopulationGene Your genotypeRef alleleAlt alleleZygosity Weight
+
rs1879417Italian (Southern) NOS1 T/CCThet-0.12
+
rs422858Italian (Northern) and Japanese AGTR1 C/CAChom0.225
+
rs275653Italian (Northern) and Japanese AGTR1 G/GAGhom0.45

From 3 gene variants of genes related to the renin-angiotensin system, you have 2 favorable and 1 unfavorable regarding their impact on longevity.


There are several ways to activate the sirtuin pathway if your genes are not favorable:


Control your blood pressure level

Look at pharmacogenetics: you may have a low response to angiotensin-converting enzyme (ACE) inhibitors, depending on the variants carrying, so talk to your healthcare practitioner.

Diet: A healthy diet can help prevent hypertension and improve overall cardiovascular health. Here are some dietary tips to follow: limit processed and high-fat foods, as well as sugary drinks and snacks; reduce your salt intake by using herbs and spices to flavor your food instead of salt, and avoid high-sodium packaged and processed foods; incorporate calcium-rich foods such as low-fat dairy products, tofu, and leafy greens into your diet.

The HSP (heat shock protein) genes are a group of genes that encode heat shock proteins, which are a class of chaperone proteins that help to protect cells from stress-induced damage. HSPs have been shown to play a role in a variety of cellular processes, including protein folding, DNA repair, and apoptosis. While the exact mechanisms by which HSPA genes influence aging and longevity are not yet fully understood, it is believed that they may help to protect cells from the accumulation of damage caused by stress and other environmental factors. As such, HSPs and their associated genes may be a promising target for interventions aimed at promoting healthy aging and extending lifespan. Some unfavorable variants in HSP genes have been shown to reduce the ability of cells to respond to stress, leading to increased damage and inflammation.

+
RSIDPopulationGene Your genotypeRef alleleAlt alleleZygosity Weight

From 0 gene variants related to heat-shock proteins, you have 0 favorable and 0 unfavorable.


If you have unfavorable heat shock protein (HSP) gene variants, there are several things you can do to reduce cell stress:


Environmental factors: Avoiding exposure to environmental toxins, such as cigarette smoke, pollution, and pesticides, can help reduce cellular stress and inflammation.

Sleep: Getting adequate sleep is important for reducing cellular stress and promoting cellular repair and regeneration.

Chronic inflammation is a major contributor to the aging process. Inflammation is a natural response of the immune system to harmful stimuli, such as pathogens or tissue damage. However, if this response becomes chronic, it can lead to tissue damage and the development of age-related diseases such as Alzheimer's disease, cardiovascular disease, and cancer.

Chronic inflammation is characterized by the sustained activation of the immune system and the release of pro-inflammatory molecules, such as cytokines, chemokines, and reactive oxygen species (ROS). These molecules can damage cellular components, including DNA, proteins, and lipids, leading to cellular dysfunction and death.

In addition, chronic inflammation can also activate other pathways involved in aging, such as the mTOR pathway and the senescence-associated secretory phenotype (SASP), which further exacerbate inflammation and tissue damage. Therefore, reducing chronic inflammation is a promising strategy to promote healthy aging and prevent age-related diseases.

Chronic inflammation can have a genetic component, with certain genes being associated with increased inflammation levels.

+
RSIDPopulationGene Your genotypeRef alleleAlt alleleZygosity Weight
+
rs590211American (Caucasian) PKNOX2 G/AAGhet0.07
+
rs2232548American (Caucasian) KLRF1 T/GGThet0.07
+
rs205499American (Caucasian) TRIM25 A/GGAhet0.07
+
rs6997589American (Caucasian) SH2D4A A/GGAhet0.07
+
rs4648884American (Caucasian) RUNX3 C/TTChet0.08
+
rs9517320American (Caucasian) STK24 C/AAChet0.08
+
rs2251252Italian (Southern) SDC4 A/GGAhet0.09
+
rs1981429Italian (Southern) SDC4 T/GGThet0.09
+
rs1450741Korean LYN C/TTChet0.09
+
rs2072454Korean EGFR T/CCThet0.1
+
rs3804474American (Caucasian) LY86 T/TCThom0.14
+
rs1546518Korean LYN C/CGChom0.18
+
rs5744256Italian IL18 G/GAGhom0.2

From 13 gene variants related to inflammation, you have 13 favorable and 0 unfavorable.


If you have unfavorable variants in genes involved in chronic inflammation, there are several steps you can take to improve your health outcomes potentially:


Biochemical markers for check-ups: C-reactive protein (CRP), ferritin, tumor necrosis factor-alpha (TNF-alpha).

Diet: Consuming a balanced diet that is rich in anti-inflammatory foods such as fruits, vegetables, whole grains, and fatty fish can help reduce inflammation. Some herbs and spices have an antiinflammatory action so that they can be added to the diet: garlic, ginger, turmeric, cinnamon, and oregano.

Dentist check-ups: regular dental check-ups and good oral hygiene practices can help prevent chronic inflammation in the gums and other oral tissues. Periodontal disease, which is caused by bacteria and leads to inflammation and tissue destruction in the gums, is a common cause of chronic inflammation.

Air cleaning: air pollutants are a common source of chronic inflammation. Control your air quality indoors, and use filter systems if needed.

Genome maintenance and post-transcriptional processes are both important for maintaining cellular and organismal homeostasis, and both have been implicated in the regulation of longevity.

Genome maintenance is essential for preventing DNA damage and mutations that can lead to age-related diseases and shortened lifespans. Post-transcriptional processes, including RNA splicing, translation, and decay, are important for regulating gene expression and ensuring that proteins are produced at the appropriate levels and times. Dysregulation of these processes can lead to age-related diseases and shortened lifespans.

+
RSIDPopulationGene Your genotypeRef alleleAlt alleleZygosity Weight
+
rs2805533Italian, Ashkenazi Jewish and Japanese ADARB2 A/AGAhom-0.35
+
rs2485662American (Caucasians), Italian (Southern), French, Ashkenazi Jewish LMNA C/CTChom-0.27
+
rs414743Italian, Ashkenazi Jewish and Japanese ADARB1 A/GGAhet-0.175
+
rs701176American (Caucasian) PCNX2 A/GGAhet0.07
+
rs6732163American (Caucasian) BABAM2 G/AAGhet0.07
+
rs6443429American (Caucasian) TBL1XR1 C/AAChet0.07
+
rs1800392American (Caucasian) WRN T/GGThet0.078
+
rs2838816Italian, Ashkenazi Jewish and Japanese ADARB1 A/GGAhet0.175
+
rs3024239American (Caucasian) WRN T/CCThet0.195

From 9 gene variants related to genome maintenance and post-transcriptional processes, you have 6 favorable and 3 unfavorable.


If you have unfavorable variants in genes involved in genome maintenance, there are several steps you can take to improve your health outcomes potentially:


Ensure methylation processes in your body work well: monitor blood levels of B12, B9, B2, B6, Zn, and Co[PMID: 31601260, PMID: 36203899]. These components are needed for methylation enzymes' appropriate work. Methylation is important for genome maintenance because it is involved in the regulation of gene expression and DNA repair [PMID: 34209979].

Reduce exposure to environmental toxins, such as pollution, pesticides, and chemicals. Air-control indoor systems can help with this point.

Check vitamin D level: Vitamin D plays a role in DNA repair and has been shown to have a protective effect regarding genome maintenance [PMID: 11295155].

Protect the skin from UV radiation by wearing protective clothing and using sunscreen.


Although genes associated with longevity can be classified into 11 definite pathways, there are other genes that do not fall into these categories, which are presented in this table.

Although many genes associated with longevity can be classified into 11 definite pathways, there are other genes that do not fall into these categories, which are presented in this table.

+
RSIDPopulationGene Your genotypeRef alleleAlt alleleZygosity Weight
+
rs3847663American A/GGAhet0.025
+
rs1733676American A/AGAhom0.05
+
rs2024714American (Caucasian) CDH4 T/CCThet0.065
+
rs2826891American (Caucasian) NCAM2 T/CCThet0.065
+
rs2032563American (Caucasian) CAMTA1 A/GGAhet0.07
+
rs10489436American (Caucasian) G/AAGhet0.07
+
rs11211037American (Caucasian) BTBD19 C/AAChet0.07
+
rs10923673American (Caucasian) G/TTGhet0.07
+
rs12043001American (Caucasian) C/TTChet0.07
+
rs4285687American (Caucasian) A/GGAhet0.07
+
rs6657655American (Caucasian) LOC105373215 T/CCThet0.07
+
rs2247549American (Caucasian) G/AAGhet0.07
+
rs4237774American (Caucasian) LOC107984303 A/GGAhet0.07
+
rs1834461American (Caucasian) G/AAGhet0.07
+
rs563384American (Caucasian) TENM4 G/AAGhet0.07
+
rs1470196American (Caucasian) A/GGAhet0.07
+
rs11063009American (Caucasian) A/GGAhet0.07
+
rs855137American (Caucasian) C/TTChet0.07
+
rs2660888American (Caucasian) G/AAGhet0.07
+
rs697887American (Caucasian) LINC02463 G/AAGhet0.07
+
rs1340573American (Caucasian) A/GGAhet0.07
+
rs9652250American (Caucasian) T/CCThet0.07
+
rs9513192American (Caucasian) A/CCAhet0.07
+
rs7149754American (Caucasian) LOC105370656 G/AAGhet0.07
+
rs10518725American (Caucasian) WDR72 A/GGAhet0.07
+
rs1280396American (Caucasian) CGNL1 G/AAGhet0.07
+
rs12446827American (Caucasian) G/AAGhet0.07
+
rs1005321American (Caucasian) HS3ST3B1 A/GGAhet0.07
+
rs2880540American (Caucasian) G/AAGhet0.07
+
rs8073559American (Caucasian) G/AAGhet0.07
+
rs9894254American (Caucasian) SGSH T/CCThet0.07
+
rs12606250American (Caucasian) T/CCThet0.07
+
rs2927261American (Caucasian) C/TTChet0.07
+
rs7246865American (Caucasian) MYO9B A/GGAhet0.07
+
rs11687681American (Caucasian) A/GGAhet0.07
+
rs401974American (Caucasian) C/TTChet0.07
+
rs3769583American (Caucasian) TTC27 T/CCThet0.07
+
rs2901840American (Caucasian) A/CCAhet0.07
+
rs12623542American (Caucasian) LINC01237 G/TTGhet0.07
+
rs2866705American (Caucasian) C/TTChet0.07
+
rs2253363American (Caucasian) A/GGAhet0.07
+
rs5754682American (Caucasian) LARGE1 T/CCThet0.07
+
rs12634249American (Caucasian) SUMF1 A/CCAhet0.07
+
rs751481American (Caucasian) G/AAGhet0.07
+
rs922943American (Caucasian) RARB A/GGAhet0.07
+
rs1550765American (Caucasian) G/AAGhet0.07
+
rs10084768American (Caucasian) LINC01182 A/GGAhet0.07
+
rs828154American (Caucasian) A/GGAhet0.07
+
rs358256American (Caucasian) GBA3 C/TTChet0.07
+
rs2660342American (Caucasian) G/AAGhet0.07
+
rs1230155American (Caucasian) A/GGAhet0.07
+
rs2553377American (Caucasian) A/CCAhet0.07
+
rs4461634American (Caucasian) G/AAGhet0.07
+
rs2432143American (Caucasian) ITGA1 C/TTChet0.07
+
rs158807American (Caucasian) G/TTGhet0.07
+
rs147295American (Caucasian) C/TTChet0.07
+
rs9324976American (Caucasian) C/AAChet0.07
+
rs514217American (Caucasian) G/AAGhet0.07
+
rs4245543American (Caucasian) T/CCThet0.07
+
rs11153598American (Caucasian) NT5DC1 A/CCAhet0.07
+
rs1858897American (Caucasian) G/AAGhet0.07
+
rs2738173American (Caucasian) G/AAGhet0.07
+
rs804283American (Caucasian) GATA4 A/GGAhet0.07
+
rs899430American (Caucasian) G/AAGhet0.07
+
rs4871976American (Caucasian) PHYHIP A/GGAhet0.07
+
rs7825208American (Caucasian) FGFR1 G/AAGhet0.07
+
rs1812736American (Caucasian) A/GGAhet0.07
+
rs12353067American (Caucasian) T/CCThet0.07
+
rs2590504American (Caucasian) PPP1R26-AS1 T/CCThet0.08
+
rs10149689Ashkenazi Jewish CEP128 G/AAGhet0.085
+
rs12050077Ashkenazi Jewish CEP128 A/GGAhet0.085
+
rs2498804Dutch LOC107987209 A/CCAhet0.095
+
rs1468772American (Caucasians), Italian (Southern), French, Ashkenazi Jewish SEMA4A G/GTGhom0.1
+
rs205990American (Amish) LOC105378102 G/GAGhom0.1
+
rs73598374Italian (Central) ADA T/CCThet0.115
+
rs7799039Jordanian LOC105375494 A/GGAhet0.115
+
rs12129750American (Caucasian) G/GAGhom0.14
+
rs12737127American (Caucasian) LOC105373220 C/CAChom0.14
+
rs4933309American (Caucasian) C/CTChom0.14
+
rs11218921American (Caucasian) LOC341056 C/CTChom0.14
+
rs2722222American (Caucasian) T/TCThom0.14
+
rs2014547American (Caucasian) T/TCThom0.14
+
rs2543356American (Caucasian) C/CTChom0.14
+
rs7155817American (Caucasian) G/GAGhom0.14
+
rs2277509American (Caucasian) CCDC88C A/ACAhom0.14
+
rs8098316American (Caucasian) G/GTGhom0.14
+
rs9304496American (Caucasian) KCTD1 T/TCThom0.14
+
rs11086106American (Caucasian) PGPEP1 T/TCThom0.14
+
rs1974676American (Caucasian) HPCAL1 G/GAGhom0.14
+
rs4363980American (Caucasian) LOC105373714 G/GTGhom0.14
+
rs1463990American (Caucasian) LOC107985988 A/AGAhom0.14
+
rs6115865American (Caucasian) C20orf194 T/TCThom0.14
+
rs3904864American (Caucasian) G/GAGhom0.14
+
rs2201186American (Caucasian) LOC107986178 A/AGAhom0.14
+
rs4073968American (Caucasian) LINC01258 T/TCThom0.14
+
rs975072American (Caucasian) G/GAGhom0.14
+
rs1490813American (Caucasian) C/CTChom0.14
+
rs6580511American (Caucasian) A/AGAhom0.14
+
rs303006American (Caucasian) CMAHP G/GAGhom0.14
+
rs6946852American (Caucasian) T/TCThom0.14
+
rs6991271American (Caucasian) KIF13B G/GTGhom0.14
+
rs567971American (Caucasian) C/CTChom0.14
+
rs829751American (Caucasian) G/GAGhom0.14
+
rs1016013American (Caucasian) G/GAGhom0.14
+
rs4541274American (Caucasian) CTNNA2 C/TTChet0.205
+
rs723525American (Caucasian) CTNNA2 G/AAGhet0.205
+
rs7656234American (Caucasian) SLC4A4 T/TCThom0.37
+
rs1860242American (Caucasian) CTNND2 G/GAGhom0.41

Longevity drugs

Plenty of drugs are frequently prescribed at an older age. Moreover, some drugs are known to have geroprotective action (e.g. statins, metformin, rapamycin, etc.). Drug metabolism to a large extent depends on a person’s genetic polymorphisms, affecting the activity of xenobiotics-transforming enzymes. So it’s a common situation when individual dose correction is needed, or even another drug has to be taken in order to avoid adverse effects. Longevity-drugs report is mainly based on data from PharmGKB database ( https://www.pharmgkb.org/ ) and DrugAge.

In the table you can find data about your genome’s gene variants, associated with a changed response to the drugs.

# Variant/
Haplotypes
Drug(s)Phenotype CategorySignificanceSentenceAllele Of Frequency In Cases Allele Of Frequency In ControlsRatio Stat TypeEffect
1rs2284018 lithiumEfficacy yes Genotype TT is associated with decreased response to lithium in people with Bipolar Disorder as compared to genotypes CC + CT. OR9.091
2rs7316769 duloxetineEfficacy yes Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T. OR7.692
3rs10771999 duloxetineEfficacy yes Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G. OR7.692
4rs5441 sertralineEfficacy yes Genotype GG is associated with increased response to sertraline in people with Depressive Disorder, Major as compared to genotypes AA + AG.G OR5.9
5rs7306991 duloxetineEfficacy yes Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T. OR5.882
6rs10771997 duloxetineEfficacy yes Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C. OR5.882
7rs10771998 duloxetineEfficacy yes Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G. OR5.882
8rs12595802 duloxetineEfficacy yes Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A. OR5.556
9rs12630569 duloxetineEfficacy yes Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C. OR5.556
10rs4513095 sofosbuvirEfficacy yes Allele A is associated with decreased response to sofosbuvir in people with Hepatitis C, Chronic as compared to allele C.AA OR5.54
11rs7563206 methotrexateEfficacy yes Genotypes CT + TT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.CC OR5.0
12rs7787082 clozapineEfficacy yes Allele G is associated with decreased response to clozapine in people with Schizophrenia as compared to allele A.A OR4.87
13rs3087403 cisplatinEfficacy yes Genotypes CT + TT are associated with increased response to cisplatin in people with Osteosarcoma as compared to genotype CC.T OR4.44
14rs1056827 risperidoneEfficacy no Allele A is associated with decreased response to risperidone in people with Schizophrenia as compared to allele C.AA OR4.37
15rs243865 ulinastatinEfficacy yes Allele T is associated with decreased response to ulinastatin in people with Pancreatitis as compared to allele C.TT OR4.121
16rs622342 metforminEfficacy yes Genotypes AC + CC is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype AA.A OR4.1
17rs11591741 ustekinumabEfficacy yes Genotypes CC + CG is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype GG. OR33.333
18rs1801133 fluorouracilEfficacy yes Genotypes AA + AG is associated with increased response to fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.A OR3.8
19rs4437856 duloxetineEfficacy yes Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C. OR3.704
20rs2419128 duloxetineEfficacy yes Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T. OR3.704
21rs12094644 duloxetineEfficacy yes Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A. OR3.704
22rs1883112 idarubicinEfficacy yes Genotype AA is associated with increased response to idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype GG.A OR3.7
23rs4633 risperidoneEfficacy no Allele T is associated with decreased response to risperidone in people with Schizophrenia as compared to allele C.TT OR3.56
24rs10007051 duloxetineEfficacy yes Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T. OR3.448
25rs11933890 duloxetineEfficacy yes Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G. OR3.333
26rs62319299 duloxetineEfficacy yes Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C. OR3.333
27rs56229625 duloxetineEfficacy yes Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T. OR3.333
28rs55881666 duloxetineEfficacy yes Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T. OR3.333
29rs4639250 duloxetineEfficacy yes Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C. OR3.333
30rs12657120 duloxetineEfficacy yes Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C. OR3.226
31rs10012 risperidoneEfficacy no Allele C is associated with decreased response to risperidone in people with Schizophrenia as compared to allele G.CC OR3.16
32rs2270007 citalopramEfficacy yes Genotypes CC + CG are associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotype GG.CC OR2.93
33rs8636 amisulprideEfficacy yes Genotype CT is associated with increased response to amisulpride in people with Schizophrenia as compared to genotypes CC + TT.CC OR2.91
34rs6498169 glatiramer acetateEfficacy yes Allele A is associated with increased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele G.AA OR2.86
35rs2284017 lithiumEfficacy not stated Allele C is associated with increased response to lithium in people with Bipolar Disorder as compared to allele T. OR2.857
36rs316019 metforminEfficacy yes Genotypes AA + AC is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype CC.AA OR2.857
37rs1695 cyclophosphamideEfficacy no Genotypes AG + GG is associated with decreased response to cyclophosphamide in people with Lupus Nephritis as compared to genotype AA.GG OR2.8
38rs3749442 cannabidiolEfficacy yes Genotypes AA + AG are associated with decreased response to cannabidiol in people with Epilepsy as compared to genotype GG. OR2.778
39rs2114358 glatiramer acetateEfficacy yes Allele A is associated with increased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele G.AA OR2.77
40rs11869731 lithiumEfficacy yes Genotype CC is associated with increased response to lithium in people with Bipolar Disorder as compared to genotypes CG + GG.CC OR2.39
41rs4818 risperidoneEfficacy no Allele G is associated with increased response to risperidone in people with Schizophrenia as compared to allele C.CC OR2.381
42rs3747178 ethosuximideEfficacy yes Allele T is associated with decreased clinical benefit to ethosuximide in children with Epilepsy as compared to allele C.TT OR2.38
43rs1800469 glatiramer acetateEfficacy yes Allele A is associated with decreased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele G.AA OR2.326
44rs165599 bupropionEfficacy yes Genotypes AA + AG are associated with increased response to bupropion in smokers as compared to genotype GG.A OR2.21
45rs1801058 metoprololEfficacy yes Genotype CT is associated with decreased response to metoprolol in women with hypertensive nephrosclerosis as compared to genotype CC. HR2.174
46rs2631372 imatinibEfficacy yes Genotypes CG + GG are associated with increased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC. HR2.174
47rs680244 Drugs used in nicotine dependenceOther yes Allele T is associated with increased response to Drugs used in nicotine dependence in people with Tobacco Use Disorder. HR2.083
48rs616147 creatineEfficacy yes Genotypes AA + AG are associated with increased response to creatine in people with Amyotrophic Lateral Sclerosis as compared to genotype GG.A HR2.083
49rs1495741 iguratimodEfficacy yes Genotypes AG + GG is associated with decreased clinical benefit to iguratimod in people with Arthritis, Rheumatoid as compared to genotype AA.GG OR2.008
50rs1012335 glatiramer acetateEfficacy yes Allele G is associated with decreased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele C.GG OR13.889
51rs11042725 paroxetineEfficacy yes Genotype CC is associated with decreased response to paroxetine in people with Depressive Disorder, Major as compared to genotypes AA + AC. OR13.333
52rs9923231 acenocoumarolDosage yes Genotype TT is associated with decreased dose of acenocoumarol as compared to genotypes CC + CT.T OR11.6
53rs1329428 ranibizumabEfficacy no Allele C is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T. OR1.961
54rs3763980 methotrexateEfficacy yes Allele A is associated with decreased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele T. OR1.887
55rs10033900 ranibizumabEfficacy no Allele C is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T. OR1.887
56rs3781719 botulinum toxin type aEfficacy yes Allele G is associated with decreased response to botulinum toxin type a in women with Migraine NOS as compared to allele A.GG OR1.88
57rs2631370 imatinibDosage no Allele C is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele T.C OR1.87
58rs2010963 imatinibDosage no Allele C is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.C OR1.852
59rs2804402 methotrexateToxicity no Allele A is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele G.G HR1.79
60rs1800544 methylphenidateEfficacy no Allele G is associated with decreased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity as compared to allele C. OR1.786
61rs6990851 anastrozoleEfficacy yes Allele G is associated with increased response to anastrozole in women with Breast Neoplasms as compared to allele A. HR1.786
62rs8109525 bupropionEfficacy yes Genotype GG is associated with increased response to bupropion in people with Tobacco Use Disorder as compared to genotypes AA + AG.G OR1.78
63rs1410996 ranibizumabEfficacy no Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele G. OR1.754
64rs2032582 imatinibEfficacy no Allele T is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele A.GA OR1.754
65rs2032582 imatinibEfficacy no Allele T is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele A.GA OR1.754
66rs7574865 adalimumabEfficacy no Allele T is not associated with response to adalimumab in people with Arthritis, Rheumatoid as compared to allele G.T OR1.724
67rs628031 imatinibEfficacy yes Genotypes AA + AG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG. OR1.724
68rs2229437 benazeprilEfficacy yes Genotypes GG + GT are associated with decreased response to benazepril in people with Hypertension as compared to genotype TT.T OR1.667
69rs10737680 ranibizumabEfficacy no Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele C. OR1.613
70rs12231740 methotrexateEfficacy yes Allele T is associated with decreased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele C. OR1.587
71rs20455 pravastatinEfficacy yes Genotypes AG + GG are associated with increased response to pravastatin in people with Myocardial Infarction as compared to genotype AA. HR1.587
72rs2236259 methadoneEfficacy no Allele C is not associated with response to methadone in people with Heroin Dependence as compared to allele T.T OR1.587
73rs3204953 cisplatinEfficacy no Genotypes CT + TT are not associated with increased response to cisplatin in people with Osteosarcoma as compared to genotype CC.T OR1.56
74rs3212986 cisplatinEfficacy yes Allele A is associated with decreased response to cisplatin in women with Ovarian Neoplasms as compared to allele C.A OR1.53
75rs249429 metforminEfficacy no Allele T is not associated with response to metformin in people with Diabetes Mellitus as compared to allele C.CT OR1.471
76rs3852209 nicotineEfficacy yes Genotypes CT + TT are associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotype CC.T OR1.46
77rs7905446 nortriptylineEfficacy no Genotype TT is not associated with response to nortriptyline in people with Depression as compared to genotypes GG + GT. OR1.441
78rs2494732 risperidoneEfficacy no Allele T is not associated with response to risperidone in people with Schizophrenia as compared to allele C.TT OR1.414
79rs274717 gemcitabineEfficacy no Genotypes AG + GG are associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. HR1.408
80rs2960306 metoprololEfficacy no Genotype TT is not associated with decreased response to metoprolol in women with hypertensive nephrosclerosis as compared to genotype GG. HR1.389
81rs2811332 lithiumEfficacy no Allele C is not associated with response to lithium in people with Bipolar Disorder as compared to allele G.CC OR1.36
82rs2236256 methadoneEfficacy no Allele C is not associated with response to methadone in people with Heroin Dependence as compared to allele A.A OR1.35
83rs3736544 lithiumEfficacy no Allele A is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele G.A OR1.333
84rs2082940 pioglitazoneEfficacy no Genotype CC are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotypes CT + TT.CT OR1.303
85rs16969968 nicotineOther no Allele A is not associated with exposure to nicotine in men as compared to allele G.A OR1.3
86rs2306283 atorvastatinEfficacy yes Genotype AA is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes AG + GG.G OR1.29
87rs8065082 metforminEfficacy yes Genotypes CT + TT is associated with increased response to metformin in people with Glucose Intolerance as compared to genotype CC. HR1.282
88rs1800797 peginterferon alfa-2aEfficacy yes Allele G is associated with decreased response to peginterferon alfa-2a in people with Hepatitis C, Chronic as compared to allele A. RR1.282
89rs1800796 peginterferon alfa-2aEfficacy yes Allele G is associated with decreased response to peginterferon alfa-2a in people with Hepatitis C, Chronic as compared to allele C. RR1.282
90rs1800795 peginterferon alfa-2aEfficacy yes Allele G is associated with decreased response to peginterferon alfa-2a in people with Hepatitis C, Chronic as compared to allele C. RR1.282
91rs6313 risperidoneEfficacy no Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G.AA OR1.274
92rs699947 imatinibDosage no Allele C is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele A.C OR1.27
93rs868755 imatinibDosage no Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.T OR1.266
94rs1063538 pioglitazoneEfficacy no Genotypes CC + CT are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotype TT.CT OR1.255
95rs1800532 venlafaxineEfficacy no Allele G is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele T. OR1.25
96rs12205732 methadoneDosage no Allele A is not associated with dose of methadone in people with Heroin Dependence as compared to allele G.A OR1.242
97rs762551 imatinibDosage yes Genotype CC is associated with decreased dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AA + AC.C OR1.235
98rs2295553 methotrexateEfficacy no Allele C is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T. OR1.235
99rs2740574 amlodipineEfficacy no Genotypes CT + TT are not associated with response to amlodipine in people with Hypertension as compared to genotype CC. HR1.235
100rs6280 clozapineEfficacy not stated Allele T is not associated with response to clozapine in people with Schizophrenia as compared to allele C. OR1.22
101rs17035723 acamprosateEfficacy no Allele T is not associated with response to acamprosate in people with Alcoholism as compared to allele C. HR1.22
102rs266729 pioglitazoneEfficacy no Genotype CC are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotypes CG + GG.GC OR1.219
103rs3774261 pioglitazoneEfficacy no Genotypes AG + GG are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotype AA.GA OR1.209
104rs1329424 ranibizumabEfficacy no Allele G is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T. OR1.205
105rs2278749 lithiumEfficacy no Allele T is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.T OR1.18
106rs11212617 metforminEfficacy no Allele C is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele A. OR1.163
107rs9828223 adalimumabEfficacy yes Allele T is associated with decreased response to adalimumab in people with Crohn Disease as compared to allele C.T OR1.16
108rs2231142 sulfasalazineOther no Allele T is not associated with discontinuation of sulfasalazine in people with Arthritis, Rheumatoid as compared to allele G.T HR1.15
109rs1042522 oxaliplatinEfficacy yes Genotypes CG + GG is associated with decreased response to oxaliplatin in people with Colorectal Neoplasms as compared to genotype CC.G HR1.136
110rs683369 imatinibDosage no Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.G OR1.136
111rs3821799 pioglitazoneEfficacy no Genotypes CT + TT are not associated with response to pioglitazone in people with Diabetes Mellitus as compared to genotype CC.CT OR1.131
112rs2244500 methotrexateEfficacy no Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G. OR1.124
113rs6506569 methotrexateEfficacy no Allele C is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T. OR1.124
114rs293983 belimumabEfficacy no Allele T is not associated with response to belimumab in people with Lupus erythematosus as compared to allele C. OR1.111
115rs1390913 lithiumEfficacy no Allele A is not associated with response to lithium in people with Bipolar Disorder as compared to allele G.AA OR1.11
116rs6495307 nicotineOther no Allele T is not associated with exposure to nicotine in men as compared to allele C.T OR1.1
117rs6347 methadoneDosage no Allele C is not associated with dose of methadone in people with Heroin Dependence as compared to allele T.C OR1.09
118rs2013169 methylphenidateEfficacy no Allele T is associated with decreased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity. OR1.087
119rs662 clopidogrelEfficacy no Genotypes CC + CT is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype TT.T HR1.087
120rs3808627 heroinDosage no Allele T is not associated with dose of heroin in people with Heroin Dependence as compared to allele C.T OR1.082
121rs1947274 methylphenidateEfficacy no Allele A is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C. OR1.053
122rs6902403 methadoneEfficacy no Allele C is not associated with response to methadone in people with Heroin Dependence as compared to allele T.T OR1.053
123rs3212964 cisplatinEfficacy no Allele T is not associated with response to cisplatin in women with Ovarian Neoplasms as compared to allele C.T OR1.05
124rs4483927 risperidoneEfficacy no Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele T.GG OR1.033
125rs2071559 imatinibDosage no Allele A is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.A OR1.02
126rs3393 methotrexateToxicity no Allele C is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T.C HR1.01
127rs11568817 venlafaxineEfficacy no Allele C is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele A. OR1.01
128rs2230199 eculizumabEfficacy no Genotypes CC + CG is not associated with response to eculizumab in people with paroxysmal nocturnal hemoglobinuria as compared to genotype GG.C OR1.0
129rs5836788 methotrexateEfficacy no Allele del is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C. OR1.0
130rs3827020 nicotineOther no Allele C is not associated with exposure to nicotine in men as compared to allele T.C OR1.0
131rs2072660 vareniclineEfficacy no Genotypes CT + TT are not associated with response to varenicline in people with Tobacco Use Disorder as compared to genotype CC. OR0.99
132rs1051740 carbamazepineEfficacy no Genotype TT is not associated with resistance to carbamazepine in people with Epilepsy as compared to genotypes CC + CT.CT OR0.98
133rs1024323 metoprololEfficacy no Genotype CC is not associated with decreased response to metoprolol in women with hypertensive nephrosclerosis as compared to genotype TT. HR0.98
134rs1805054 risperidoneEfficacy no Allele T is not associated with response to risperidone in people with Schizophrenia as compared to allele C.TT OR0.973
135rs699517 methotrexateEfficacy no Allele T is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C. OR0.971
136rs9567746 venlafaxineEfficacy no Allele A is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele G. OR0.962
137rs3212961 cisplatinEfficacy no Allele A is not associated with response to cisplatin in women with Ovarian Neoplasms as compared to allele G.A OR0.962
138rs743572 abirateroneEfficacy no Genotypes AG + GG are not associated with response to abiraterone in men with Prostatic Neoplasms as compared to genotype AA.G HR0.96
139rs6912029 heroinDosage no Allele T is not associated with dose of heroin in people with Heroin Dependence as compared to allele G.T OR0.955
140rs3394 methotrexateToxicity no Allele C is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T.T HR0.952
141rs2234922 carbamazepineEfficacy no Genotype AA is not associated with resistance to carbamazepine in people with Epilepsy as compared to genotypes AG + GG.AG OR0.952
142rs6296 venlafaxineEfficacy no Allele C is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele G. OR0.952
143rs6935207 imatinibDosage no Allele A is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.A OR0.94
144rs6551665 methylphenidateEfficacy no Allele A is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele G. OR0.935
145rs1049305 cisplatinEfficacy no Genotypes CC + CG are not associated with response to cisplatin in people with Mesothelioma as compared to genotype GG. HR0.926
146rs228666 lithiumEfficacy no Allele C is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele T.C OR0.92
147rs2236257 methadoneEfficacy no Allele C is not associated with response to methadone in people with Heroin Dependence as compared to allele G.C OR0.92
148rs615470 nicotineOther no Allele T is not associated with exposure to nicotine in men as compared to allele C.T OR0.909
149rs228642 lithiumEfficacy no Allele C is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele T.C OR0.901
150rs2279287 lithiumEfficacy no Allele T is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.T OR0.901
151rs2631367 imatinibDosage no Allele C is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.G OR0.9
152rs12666409 methadoneDosage no Allele A is not associated with dose of methadone in people with Heroin Dependence as compared to allele T.A OR0.896
153rs5320 methadoneDosage no Allele A is not associated with dose of methadone in people with Heroin Dependence as compared to allele G.A OR0.895
154rs130058 venlafaxineEfficacy no Allele A is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele T. OR0.893
155rs4810083 metforminEfficacy no Allele T is not associated with response to metformin in people with Diabetes Mellitus as compared to allele C.CT OR0.89
156rs1136287 ranibizumabEfficacy no Allele C is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T. OR0.885
157rs4343 sertralineEfficacy no Genotype GG is not associated with response to sertraline in people with Depressive Disorder.GG OR0.885
158rs2640909 lithiumEfficacy no Allele C is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele T.C OR0.88
159rs228729 lithiumEfficacy no Allele T is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.T OR0.877
160rs1045280 nicotineEfficacy no Allele C is not associated with response to nicotine in people with Tobacco Use Disorder as compared to allele T.C OR0.877
161rs2236196 vareniclineEfficacy no Genotypes AA + AG is not associated with response to varenicline in people with Tobacco Use Disorder as compared to genotype GG. OR0.87
162rs9322453 heroinDosage no Allele C is not associated with dose of heroin in people with Heroin Dependence as compared to allele G.C OR0.865
163rs129915 methadoneDosage no Allele G is not associated with dose of methadone in people with Heroin Dependence as compared to allele A.G OR0.861
164rs27072 methadoneDosage no Allele T is not associated with dose of methadone in people with Heroin Dependence as compared to allele C.T OR0.858
165rs6064463 methotrexateEfficacy no Allele C is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T. OR0.855
166rs735482 cisplatinEfficacy no Allele C is not associated with response to cisplatin in women with Ovarian Neoplasms as compared to allele A.C OR0.85
167rs10011796 allopurinolEfficacy no Genotypes CT + TT are not associated with response to allopurinol in people with Gout as compared to genotype CC.CT OR0.85
168rs12529 abirateroneEfficacy no Genotypes CC + CG are not associated with response to abiraterone in men with Prostatic Neoplasms as compared to genotype GG.C HR0.847
169rs1800497 risperidoneEfficacy no Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G.AA OR0.845
170rs4982133 methotrexateEfficacy no Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C. OR0.84
171rs316009 metforminEfficacy yes Genotype TT is associated with increased response to metformin in people with Diabetes Mellitus as compared to genotypes CC + CT. OR0.826
172rs1176713 risperidoneEfficacy no Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele A.GG OR0.819
173rs3842727 methadoneDosage no Allele T is not associated with dose of methadone in people with Heroin Dependence as compared to allele G.G OR0.807
174rs12979860 peginterferon alfa-2bEfficacy no Genotype CC is not associated with increased response to peginterferon alfa-2b in people with Hepatitis B, Chronic as compared to genotype CT. OR0.806
175rs12693402 lithiumEfficacy no Allele C is not associated with response to lithium in people with Bipolar Disorder as compared to allele T.CC OR0.8
176rs4680 levodopaDosage no Genotype AA is not associated with dose of levodopa in people with Parkinson Disease as compared to genotype GG.A OR0.8
177rs699946 ranibizumabEfficacy no Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele G. OR0.8
178rs800292 ranibizumabEfficacy no Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele G. OR0.794
179rs5888 ranibizumabEfficacy no Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele G. OR0.781
180rs2650972 methotrexateEfficacy no Allele T is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C. OR0.781
181rs10770140 methadoneDosage no Allele T is not associated with dose of methadone in people with Heroin Dependence as compared to allele C.C OR0.766
182rs2160734 acamprosateEfficacy no Allele C is not associated with response to acamprosate in people with Alcoholism as compared to allele T.CC HR0.763
183rs3761372 methylphenidateEfficacy no Allele T is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity. OR0.763
184rs3787429 risperidoneEfficacy no Allele T is not associated with response to risperidone in people with Schizophrenia as compared to allele C.TT OR0.756
185rs34897046 lithiumEfficacy no Allele C is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele G. OR0.746
186rs162040 methotrexateEfficacy no Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C. OR0.741
187rs10770141 methadoneDosage no Allele G is not associated with dose of methadone in people with Heroin Dependence as compared to allele A.A OR0.73
188rs3792452 methylphenidateEfficacy not stated Genotype CT is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC. OR0.714
189rs929740 methylphenidateEfficacy no Allele G is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity. OR0.714
190rs2236258 methadoneEfficacy no Allele C is not associated with response to methadone in people with Heroin Dependence as compared to allele T.C OR0.714
191rs6973474 buprenorphineEfficacy yes Allele T is associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to allele C. OR0.712
192rs4291 sertralineEfficacy no Genotype TT is not associated with response to sertraline in people with Depressive Disorder.TT OR0.709
193rs3745274 efavirenzEfficacy yes Genotypes GT + TT are associated with decreased resistance to efavirenz in people with HIV Infections as compared to genotype GG.TT OR0.7
194rs13169373 buprenorphineEfficacy yes Allele T is associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to allele C. OR0.696
195rs12943590 metforminEfficacy yes Genotypes AA + AG is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype GG.AA OR0.68
196rs274713 gemcitabineEfficacy yes Genotype GG is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT. HR0.671
197rs465646 cisplatinEfficacy no Genotypes AG + GG are not associated with increased response to cisplatin in people with Osteosarcoma as compared to genotype AA.G OR0.667
198rs1799836 levodopaDosage no Genotype TT is not associated with dose of levodopa in women with Parkinson Disease as compared to genotype CC.T OR0.667
199rs9032 methylphenidateEfficacy no Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity. OR0.658
200rs28362731 cisplatinEfficacy no Genotype AG is not associated with response to cisplatin in people with Mesothelioma as compared to genotype GG. HR0.641
201rs1061170 photodynamic therapyEfficacy no Genotype TT is not associated with response to photodynamic therapy in people with Macular Degeneration as compared to genotype CC.C OR0.637
202rs4627790 methylphenidateEfficacy no Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity. OR0.629
203rs35661809 salbutamolEfficacy yes Allele G is associated with increased response to salbutamol in children with as compared to allele A. OR0.629
204rs3803300 risperidoneEfficacy no Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.CC OR0.628
205rs610604 ustekinumabEfficacy no Genotype GG is not associated with response to ustekinumab in people with Psoriasis as compared to genotype TT.G OR0.625
206rs12248560 clopidogrelEfficacy no Genotypes CT + TT is not associated with response to clopidogrel in people with Coronary Artery Disease as compared to genotype CC.T OR0.62
207rs11559290 methylphenidateEfficacy no Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity. OR0.617
208rs3212980 cisplatinEfficacy no Genotype GT is associated with increased response to cisplatin in women with Ovarian Neoplasms as compared to genotype TT.G OR0.61
209rs73598374 methotrexateToxicity no Allele C is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T.T HR0.61
210rs4562 methylphenidateEfficacy no Allele A is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity. OR0.606
211rs2799018 methylphenidateEfficacy no Allele T is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity. OR0.599
212rs2242446 venlafaxineEfficacy yes Genotype CC is associated with increased response to venlafaxine in people with Depressive Disorder, Major as compared to genotypes CT + TT.C OR0.599
213rs17834628 salbutamolEfficacy yes Allele A is associated with increased response to salbutamol in children with as compared to allele G. OR0.599
214rs678849 buprenorphineEfficacy yes Genotype CC is associated with decreased response to buprenorphine in people with Opioid-Related Disorders as compared to genotypes CT + TT. RR0.592
215rs11280056 fluorouracilEfficacy yes Genotype TTAAAGTTA/del is associated with decreased response to fluorouracil in people with Colorectal Neoplasms as compared to genotype del/del. HR0.592
216rs4358872 methadoneDosage no Genotype GG is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotypes GT + TT. OR0.59
217rs1045642 sunitinibEfficacy yes Genotype AA is associated with decreased response to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.A HR0.588
218rs1801274 cetuximabEfficacy yes Genotype GG is associated with increased response to cetuximab in people with Head and Neck Neoplasms as compared to genotypes AA + AG.A HR0.585
219rs581111 buprenorphineEfficacy yes Genotypes AA + AG is associated with decreased response to buprenorphine in women with Opioid-Related Disorders as compared to genotype GG. RR0.581
220rs4805162 methylphenidateEfficacy no Allele G is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity. OR0.581
221rs5569 methylphenidateEfficacy yes Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG. OR0.578
222rs7118900 methadoneDosage no Genotypes AA + AG are associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype GG. OR0.57
223rs2336219 cisplatinEfficacy no Genotypes AG + GG are associated with increased response to cisplatin in women with Ovarian Neoplasms as compared to genotype AA.A OR0.56
224rs529520 buprenorphineEfficacy yes Genotype AA is associated with decreased response to buprenorphine in women with Opioid-Related Disorders as compared to genotype CC. RR0.556
225rs13120400 methotrexateEfficacy yes Genotype CC is associated with increased response to methotrexate in people with Psoriasis as compared to genotypes CT + TT. OR0.556
226rs3810818 methylphenidateEfficacy no Allele A is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity. OR0.552
227rs675026 methadoneEfficacy no Allele G is not associated with response to methadone in people with Heroin Dependence as compared to allele A.A OR0.552
228rs7719775 platinumEfficacy no Genotype AA is associated with decreased response to platinum in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG. OR0.549
229rs756770 buprenorphineEfficacy yes Allele A is associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to allele C. OR0.538
230rs1044457 gemcitabineEfficacy yes Genotype CC is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT. HR0.526
231rs429358 ranibizumabEfficacy no Allele C is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T. OR0.526
232rs2153628 indomethacinEfficacy yes Allele G is associated with increased response to indomethacin as compared to allele A. OR0.521
233rs2279343 bupropionEfficacy yes Genotype AA is associated with increased response to bupropion in people with Tobacco Use Disorder as compared to genotypes AG + GG.AG OR0.521
234rs6269 quetiapineEfficacy yes Allele A is associated with decreased response to quetiapine in people with Schizophrenia as compared to allele G. OR0.516
235rs35687416 gemcitabineEfficacy yes Genotype GG is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT. HR0.515
236rs3087386 cisplatinEfficacy no Genotypes AA + AG are not associated with increased response to cisplatin in people with Osteosarcoma as compared to genotype GG.A OR0.51
237rs1128503 sunitinibEfficacy no Genotype AA is not associated with response to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.GA OR0.5
238rs1048786 methylphenidateEfficacy no Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity. OR0.493
239rs6878291 platinumEfficacy yes Genotype GG is associated with decreased response to platinum in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.GG OR0.49
240rs776746 sunitinibDosage yes Allele T is associated with decreased dose of sunitinib in people with Carcinoma, Renal Cell as compared to allele C. OR0.49
241rs7624046 ritodrineEfficacy yes Genotype TT is associated with decreased response to ritodrine as compared to genotypes CC + CT. HR0.485
242rs2053044 ramiprilEfficacy yes Genotypes AA + AG is associated with increased response to ramipril in people with Hypertension as compared to genotype GG. HR0.478
243rs10835210 methadoneDosage no Genotype CC is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes AA + AC. OR0.467
244rs12409352 methylphenidateEfficacy no Allele A is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity. OR0.465
245rs3210967 methylphenidateEfficacy no Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity. OR0.465
246rs10465180 clozapineEfficacy yes Genotype CC is associated with decreased response to clozapine in people with Schizophrenia as compared to genotypes CT + TT. OR0.465
247rs4149117 imatinibEfficacy yes Genotypes GG + GT is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT. OR0.461
248rs7311358 imatinibEfficacy yes Genotypes AA + AG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG. OR0.461
249rs1801394 methotrexateEfficacy yes Genotypes AG + GG is associated with increased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotype AA. OR0.457
250rs1051266 methotrexateEfficacy yes Genotypes CT + TT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.T OR0.455
251rs523349 abirateroneEfficacy yes Genotype CC is associated with increased response to abiraterone in men with Prostatic Neoplasms as compared to genotypes CG + GG.C HR0.43
252rs2838958 methotrexateEfficacy yes Genotype AA is associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG. HR0.427
253rs6545816 hydroxyureaEfficacy no Allele A is not associated with increased response to hydroxyurea in people with beta-Thalassemia.AA OR0.417
254rs1799983 salvianolic acid bEfficacy yes Genotype GG is associated with increased response to salvianolic acid b in people with Coronary Disease as compared to genotypes GT + TT.T OR0.408
255rs4938013 clozapineEfficacy no Allele C is not associated with response to clozapine in people with Schizophrenia as compared to allele A.A OR0.402
256rs12610827 olanzapineEfficacy yes Allele T is associated with increased clinical benefit to olanzapine in people with Schizophrenia as compared to allele G. OR0.402
257rs1800470 rituximabEfficacy yes Genotype AG is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotype AA. OR0.385
258rs462779 cisplatinEfficacy yes Genotypes AG + GG are associated with decreased response to cisplatin in people with Osteosarcoma as compared to genotype AA.G OR0.385
259rs2233945 etanerceptEfficacy yes Allele C is associated with decreased response to etanercept in people with Arthritis, Rheumatoid as compared to allele A.A OR0.37
260rs7703002 platinumEfficacy no Genotype AA is associated with decreased response to platinum in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC. OR0.366
261rs2853539 methotrexateEfficacy yes Genotype AA is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G. OR0.362
262rs3077 peginterferon alfa-2bEfficacy yes Genotype GG is associated with increased response to peginterferon alfa-2b in people with Hepatitis B, Chronic as compared to genotypes AA + AG. OR0.36
263rs1731017 valproic acidEfficacy no Genotypes AA + AG is associated with increased resistance to valproic acid in people with Epilepsy as compared to genotype GG.AA OR0.358
264rs11615 cisplatinEfficacy yes Allele A is associated with decreased response to cisplatin in women with Ovarian Neoplasms as compared to allele G.A OR0.348
265rs3212227 methotrexateOther no Allele G is not associated with response to methotrexate in people with Psoriasis as compared to allele T. OR0.347
266rs6785930 clopidogrelEfficacy yes Genotypes AA + AG is associated with increased resistance to clopidogrel as compared to genotype GG. OR0.346
267rs324026 olanzapineEfficacy yes Allele C is associated with increased clinical benefit to olanzapine in people with Schizophrenia as compared to allele T.CC OR0.345
268rs28386840 methylphenidateEfficacy yes Genotypes AT + TT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA. OR0.341
269rs1232027 methotrexateEfficacy yes Allele A is associated with increased response to methotrexate in people with Arthritis, Psoriatic as compared to allele G. OR0.334
270rs12708954 atomoxetineEfficacy yes Allele A is associated with increased response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to allele C. OR0.323
271rs1643650 methotrexateEfficacy no Genotypes CC + CT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.CC OR0.31
272rs833061 ranibizumabEfficacy no Allele C is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T. OR0.291
273rs7079 benazeprilEfficacy yes Genotype GG is associated with response to benazepril in women with Hypertension as compared to genotype TT. OR0.286
274rs4646 tamoxifenEfficacy yes Genotype AA is associated with decreased response to tamoxifen in women with Breast Neoplasms and Menopause as compared to genotypes AC + CC.A HR0.277
275rs6809699 clopidogrelEfficacy yes Genotypes AA + AC is associated with increased resistance to clopidogrel as compared to genotype CC. OR0.272
276rs11269124 clonidineEfficacy yes Genotypes GGGGAGCTTTCCCAGAGACCC/del + del/del are associated with increased response to clonidine in people with Liver Cirrhosis as compared to genotype GGGGAGCTTTCCCAGAGACCC/GGGGAGCTTTCCCAGAGACCC. OR0.258
277rs12539 cannabidiolEfficacy yes Genotypes CT + TT are associated with increased response to cannabidiol in people with Epilepsy as compared to genotype CC. OR0.253
278rs10248420 clozapineEfficacy yes Allele A is associated with decreased response to clozapine in people with Schizophrenia as compared to allele G.A OR0.244
279rs25487 fluorouracilEfficacy yes Genotype CC is associated with increased response to fluorouracil in people with Rectal Neoplasms as compared to genotype CT. OR0.239
280rs10124893 duloxetineEfficacy yes Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A. OR0.239
281rs3784864 methotrexateEfficacy yes Genotypes AG + GG are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. OR0.236
282rs2070762 methylphenidateEfficacy yes Genotype GG is associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG. OR0.231
283rs12083537 tocilizumabEfficacy yes Genotype AA is associated with increased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.G OR0.23
284rs12502866 duloxetineEfficacy yes Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A. OR0.229
285rs3811381 eculizumabEfficacy no Genotypes CG + GG is not associated with response to eculizumab in people with paroxysmal nocturnal hemoglobinuria as compared to genotype CC.C OR0.227
286rs10123866 duloxetineEfficacy yes Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A. OR0.227
287rs7472 duloxetineEfficacy yes Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A. OR0.227
288rs7035619 duloxetineEfficacy yes Allele A is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T. OR0.227
289rs6479008 duloxetineEfficacy yes Allele C is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A. OR0.227
290rs10989064 duloxetineEfficacy yes Allele T is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele C. OR0.227
291rs9873889 duloxetineEfficacy yes Allele C is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T. OR0.216
292rs9879065 duloxetineEfficacy yes Allele C is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T. OR0.216
293rs3213422 leflunomideEfficacy yes Genotype CC is associated with increased clinical benefit to leflunomide in people with Arthritis, Rheumatoid as compared to genotypes AA + AC.A OR0.212
294rs1799732 bupropionEfficacy yes Genotype GG is associated with increased response to bupropion in people with Tobacco Use Disorder as compared to genotypes G/del + del/del. OR0.2
295rs2853542 methotrexateEfficacy yes Genotype GG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CG.GG OR0.185
296rs1427407 hydroxyureaEfficacy yes Allele T is associated with increased response to hydroxyurea in people with beta-Thalassemia as compared to allele G.TT OR0.164
297rs150929 imatinibEfficacy yes Genotypes GG + GT is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT. OR0.157
298rs2276302 clozapineEfficacy yes Allele G is associated with increased response to clozapine in people with Schizophrenia as compared to allele A.G OR0.152
299rs9332238 warfarinDosage yes Allele G is associated with increased dose of warfarin as compared to allele A. OR0.147
300rs2274567 eculizumabEfficacy yes Genotypes AG + GG is associated with decreased response to eculizumab in people with paroxysmal nocturnal hemoglobinuria as compared to genotype AA.A OR0.138
301rs9310657 duloxetineEfficacy yes Allele T is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele G. OR0.115
302rs9310658 duloxetineEfficacy yes Allele C is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T. OR0.115
303rs7616119 duloxetineEfficacy yes Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele C. OR0.115
304rs7653345 duloxetineEfficacy yes Allele A is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele G. OR0.115
305rs9819548 duloxetineEfficacy yes Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A. OR0.115
306rs13093500 duloxetineEfficacy yes Allele T is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A. OR0.115
307rs9824595 duloxetineEfficacy yes Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T. OR0.115
308rs4334661 duloxetineEfficacy yes Allele T is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele C. OR0.115
309rs766432 hydroxyureaEfficacy yes Allele C is associated with increased response to hydroxyurea in people with beta-Thalassemia as compared to allele A.CC OR0.11
310rs10210302 adalimumabEfficacy yes Genotypes CT + TT is associated with increased response to adalimumab in people with Crohn Disease as compared to genotype CC.C OR0.106
311rs144854329 cetuximabEfficacy yes Genotype del/del is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to genotypes GGTCCCACTCTTCCCACA/GGTCCCACTCTTCCCACA + GGTCCCACTCTTCCCACA/del.GGTCCCACTCTTCCCACAGGTCCCACTCTTCCCACA OR0.1
312rs1799724 etanerceptEfficacy yes Genotypes CT + TT is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype CC. OR0.083
313rs5882 rosuvastatinEfficacy yes Allele G is associated with increased response to rosuvastatin as compared to allele A.G OR0.075
314rs2284411 methylphenidateEfficacy yes Genotype CC is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CT + TT.C OR0.07
315rs9934438 warfarinDosage yes Genotype AG is associated with increased dose of warfarin in people with Atrial Fibrillation, Cardiomyopathies, heart valve replacement, Peripheral Vascular Diseases, Pulmonary Embolism and Venous Thrombosis as compared to genotype GG.A OR0.06
316rs6311 ustekinumabEfficacy yes Genotypes CT + TT is associated with decreased response to ustekinumab in people with Psoriasis as compared to genotype CC. OR0.05
317rs1570360 sildenafilEfficacy yes Genotype AA is associated with decreased response to sildenafil in men with Erectile Dysfunction as compared to genotypes AG + GG.AA OR0.05
318rs1967554 methadoneEfficacy yes Allele C is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele A. OR0.049
319rs988748 methadoneEfficacy yes Allele C is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele G. OR0.049
320rs2030324 methadoneEfficacy yes Allele G is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele A. OR0.049
321rs749671 warfarinDosage yes Allele G is associated with increased dose of warfarin as compared to allele A. OR0.049
322rs4671393 hydroxyureaEfficacy yes Allele A is associated with increased response to hydroxyurea in people with beta-Thalassemia as compared to allele G.AA OR0.047
323rs396991 rituximabEfficacy yes Genotype AA is associated with decreased response to rituximab in people with Neuromyelitis Optica as compared to genotype CC.A OR0.04
324rs191190 ustekinumabEfficacy yes Genotypes CC + CT is associated with decreased response to ustekinumab in people with Psoriasis as compared to genotype TT. OR0.035
325rs1062613 clozapineEfficacy yes Allele T is associated with increased response to clozapine in people with Schizophrenia as compared to allele C.T OR0.035

Major risks

It is not enough to have "centenarian" genes to become one: You have to cut down Your health risks before. This section contains information about the risk of developing chronic age-related diseases: cardiovascular, cancer, mental health, chronic inflammation, bone and muscle diseases, and lung diseases.

Hereditary Cancers are caused by a genetic defect that determines a higher-than-normal risk of developing cancer. Hereditary cancers can have an impact on longevity, as individuals with certain genetic mutations that increase the risk of cancer may have a shorter life expectancy. The report includes about 300 genes, related to cancer predisposition, progression and tumor cell motility.

+
# ChromPositionGeneRSIDcDNA ChangeZygosity Allele FrequencyPhenotype NameSignificance
+
1chr9 95174077FANCC rs7850958 c.346-1930T>Chom0.461417977241 not providedUncertain significance
+
2chr8 11758901GATA4 rs1062219 c.*426C>Thom0.320965164589 not providedUncertain significance
+
3chr7 140734798BRAF None c.2128-28duphetNone Noonan syndrome with multiple lentigines|Cardio-facio-cutaneous syndrome|Noonan syndrome|not specifiedConflicting interpretations of pathogenicity
+
4chr6 152121769ESR1 None c.851-3487delhet0.453276658411 Cerebellar ataxia|Emery-Dreifuss muscular dystrophyUncertain significance
+
5chr6 151842200ESR1 rs2234693 c.453-397T>Chet0.472820185244 Myocardial infarction, susceptibility torisk factor
+
6chr5 177093242FGFR4 rs351855 c.1162G>Ahom0.321121756917 See cases|Cancer progression and tumor cell motility|not specifiedConflicting interpretations of pathogenicity
+
7chr4 54738809KIT rs376694515 c.*252G>Thet0.00150015959145 Partial albinism|Mastocytosis|Gastrointestinal stromal tumorUncertain significance
+
8chr4 54296368PDGFRA None c.*1109_*1111delhet0.233246463142 Gastrointestinal stromal tumor|Idiopathic hypereosinophilic syndromeUncertain significance
+
9chr3 12583766RAF1 None c.*745_*748duphet0.0100082871167 Noonan syndrome with multiple lentigines|Noonan syndromeUncertain significance
+
10chr3 10152482VHL None c.*2540_*2545delhom0.283872598584 Von Hippel-Lindau syndromeUncertain significance
+
11chr22 41179881EP300 None c.*966_*967delhet0.0836860330896 Rubinstein-Taybi syndrome due to CREBBP mutationsUncertain significance
+
12chr22 29628628NF2 None c.115-8101delhetNone Neurofibromatosis, type 2Uncertain significance
+
13chr2 47414421MSH2 None c.942+28_942+29delhet0.100136282961 Lynch syndrome|Lynch syndrome 1|Hereditary nonpolyposis colorectal neoplasms|not specified|not providedConflicting interpretations of pathogenicity
+
14chr18 51084013SMAD4 rs1555688055 c.*5546_*5547insGCAChet0.0558176100629 Myhre syndrome|Telangiectasia, hereditary hemorrhagic, type 1|Juvenile PolyposisUncertain significance
+
15chr17 42314852STAT3 None c.*893duphet0.0704885343968 Hyper-IgE syndromeUncertain significance
+
16chr17 17212960FLCN rs775700421 c.*695C>Thet0.00086031098649 Multiple fibrofolliculomas|Familial spontaneous pneumothoraxUncertain significance
+
17chr17 7668837TP53 None c.*772delhom0.631307090039 Li-Fraumeni syndromeUncertain significance
+
18chr16 89816741FANCA rs11275235 c.-138_-126duphet0.397195961155 not specified|not providedConflicting interpretations of pathogenicity
+
19chr16 56831918NUP93 rs145146218 c.1162C>Thet0.000781664485552 Nephrotic syndrome|Nephrotic syndrome, type 12|not providedConflicting interpretations of pathogenicity
+
20chr16 2080258TSC2 rs45448801 c.3491C>Thet0.000120724060305 Tuberous sclerosis 2|Hereditary cancer-predisposing syndrome|Tuberous sclerosis syndrome|not specified|not providedConflicting interpretations of pathogenicity
+
21chr15 98963214IGF1R None c.*5789delhom0.636829615567 Growth delay due to insulin-like growth factor I resistanceUncertain significance
+
22chr15 98959855IGF1R None c.*2426delhom0.635246216486 Growth delay due to insulin-like growth factor I resistanceConflicting interpretations of pathogenicity
+
23chr15 38352242SPRED1 None c.*590_*595duphet0.0101997146933 Legius syndromeUncertain significance
+
24chr14 95090172DICER1 None c.*326delhom0.676011739265 Pleuropulmonary blastomaUncertain significance
+
25chr12 120978819HNF1A rs1169289 c.51C>Ghet0.464474334812 Type 2 diabetes mellitus|Maturity-onset diabetes of the young type 3|not specified|not providedConflicting interpretations of pathogenicity
+
26chr12 114684072TBX3 rs1555208536 c.-875_-872duphom0.41619021057 Ulnar-mammary syndrome|not providedConflicting interpretations of pathogenicity
+
27chr11 22623348FANCF rs45554234 c.*1338duphom0.959894071852 Fanconi anemiaUncertain significance
+
28chr11 535463HRAS rs8176336 c.-101C>Thom0.110307931063 Noonan syndrome and Noonan-related syndrome|not providedConflicting interpretations of pathogenicity
+
29chr10 87966903PTEN None c.*1458_*1459delhet0.231438812084 PTEN hamartoma tumor syndromeUncertain significance
+
30chr10 8074279GATA3 None c.*265duphom0.736817420436 Hypoparathyroidism, deafness, renal disease syndrome|not providedConflicting interpretations of pathogenicity
+
31chr10 8054744GATA3 None c.-503_-502duphet0.32433898974 Hypoparathyroidism, deafness, renal disease syndromeUncertain significance
+
32chr1 241500603FH None c.1237-18_1237-13duphet0.208943747471 Hereditary leiomyomatosis and renal cell cancer|Fumarase deficiency|not specified|not providedConflicting interpretations of pathogenicity
+
33chr1 241500603FH None c.1237-16_1237-13duphet0.251112909753 Hereditary leiomyomatosis and renal cell cancer|Fumarase deficiency|not specified|not providedConflicting interpretations of pathogenicity
+
34chr1 161362517SDHC rs201210474 c.*84G>Chet0.00554288917959 Pheochromocytoma|Gastrointestinal stromal tumor|Paragangliomas 3|Hereditary pheochromocytoma-paraganglioma|not specified|not providedConflicting interpretations of pathogenicity
+
35chr1 158668076SPTA1 None c.1834-16_1834-14delhet0.285708830184 Elliptocytosis|Pyropoikilocytosis, hereditary|Spherocytosis, Recessive|not providedConflicting interpretations of pathogenicity
+
36chr1 158618068SPTA1 rs28525570 c.6531-12C>Thet0.255028054441 Hemolytic anemia|Pyropoikilocytosis, hereditary|Elliptocytosis 2|Hereditary spherocytosis type 3|not specified|not providedConflicting interpretations of pathogenicity
+
37chr1 158611132SPTA1 None c.*131_*132delhet0.319211377831 Elliptocytosis|Pyropoikilocytosis, hereditary|Spherocytosis, RecessiveUncertain significance

Coronary artery disease (CAD) is a condition in which the blood vessels that supply the heart muscle with oxygen and nutrients become narrowed or blocked, leading to reduced blood flow to the heart. Age is a major risk factor for CAD, as the risk of developing CAD increases with age. Genetic factors plays an important role in the development of coronary artery disease (CAD).

This report contains data of PRS for coronary disease development (PGS000818) and the list with genes, associated with an increased risk of CAD.

However, it's important to note that genetics is just one of many factors that contribute to the development of CAD, and having a genetic predisposition to the disease does not necessarily mean that an individual will develop it.

How to read the result?

PRS is represented as a percentile within a given population. For example, you have the 70th percentile, which means your personal genetic risk of the disease development is higher than 70 out of every 100 people in a chosen population.

So percentile >50 shows an increased risk, <50 - decreased one.

TitleCoronary heart disease (PGS000818)
Sum0.5998000000000002
Count/total58/138
Average0.0051706896551724155
Percentile13%

+
# RSIDGeneRisk AlleleGenotypePubmed ID PopulationP-ValueWeight
+
1 rs8055236 CDH13 G G/GPMID 17554300; PMID 19956433; PMID 20017983;European [PMID 17554300]: 6 x 10-6-1.7
+
2 rs4977574 CDKN2B-AS1 G G/APMID 17478681; PMID 21378990; PMID 21378988; PMID 24916648; PMID: 30278588European; Asian [PMID 29263402]: 1 x 10-7; [PMID 21239051]: 1 x 10-14;-1.3
+
3 rs17465637 MIA3 C C/CPMID: 35768776; PMID 19956433; PMID 21804106; PMID 21984477; PMID 21264445;European; Iranian; [PMID 17634449]: 1 x 10-6; [PMID 21378990]: 1 x 10-8;-1.2
+
4 rs599839 SORT1 A A/APMID: 32858814; PMID 33321069; PMID: 17634449; PMID 18262040; PMID 19380133; PMID 19660754; PMID 19750184;European [PMID 33321069]: 2 x 10-7-1.2
+
5 rs17228212 SMAD3 C C/TPMID 17634449; PMID 19750184; PMID 19956433; PMID 20017983; PMID 21804106;European [PMID 17634449]: 2 x 10-7-1.1
+
6 rs1122608 LDLR G G/GPMID: 27664493; PMID 23380588; PMID 23202125; PMID 20810930; PMID 19956433; PMID: 33321069; PMID 21378990;European; Asian [PMID: 33321069]: 5 x 10-7; [PMID 21378990]: 1 x 10-9-1.0
+
7 rs383830 APC A A/APMID 26436499; PMID 17554300; PMID 21804106; PMID 19956433; PMID 21804106;European -0.9
+
8 rs1746048 CXCL12 (LINC02881) C C/CPMID: 28614256; PMID 19956433; PMID 23531450; PMID 21378990; PMID 33632238; PMID 21378990;European; Asian [PMID 33632238]: 1 x 10-6; [PMID 21378990]:3 x 10-10;-0.9
+
9 rs7250581 G G/GPMID 19955471; PMID 19956433; PMID 17554300;European -0.8
+
10 rs12413409 CNNM2 G G/GPMID 21378988; PMID 24262325; PMID: 21378990; PMID: 31228190; PMID 21378990;European [PMID 21378990]: 1 x 10-9-0.8
+
11 rs11206510 PCSK9 T C/TPMID 20864672; PMID 21378990;Multiethnic; Asian [PMID 26343387]: 2 x 10-8; [PMID 32469254]: 1 x 10-8;-0.6
+
12 rs7692387 GUCYA3 G G/GPMID: 31228190; PMID 23202125; PMID 31883534;European; Chinese [PMID: 29212778]: Discovery sample description: up to 122,733 cases, up to 424,528 controls-0.5
+
13 rs55730499 LPA T T/TPMID: 26343387Multiethnic; [PMID 26343387]: 5 x 10-39-0.4
+
14 rs3184504 SH2B3 T C/TPMID 24262325; PMID 21378990; PMID 26343387;Multiethnic -0.1
+
15 rs964184 ZPR1 G C/CPMID 19060906; PMID 20864672; PMID 21378990; PMID 22003152; PMID 21378990; PMID 28714975;European [PMID 28714975]: 5 x 10-6; [PMID 21378990]: 1 x 10-17;0.0
+
16 rs515135 APOB T C/CPMID 23202125; PMID: 30507093; PMID 29212778;European [PMID 29212778]: 6 x 10-170.0
+
17 rs2943634 C C/APMID 17634449; PMID 23659870; PMID 22042884; PMID 19956433; PMID 19750184; PMID 22207032;European [PMID 17634449]: 2 x 10-70.0
+
18 rs11591147 PCSK9 T/GPMID 30104761; PMID 28714975; PMID 23083789; PMID 18193044;European; [PMID 30104761]: 2 x 10-12; [PMID 28714975]: 3 x 10-100.7
+
19 rs6922269 MTHFD1L A A/GPMID 17634449; PMID 17554300; PMID 19164808; PMID 22216278; PMID 17634449;European [PMID 17634449]: 3 x 10-8;0.7
+
20 rs1333049 CDKN2B-AS1 C C/GPMID 17634449, PMID 18362232; PMID 20031606; PMID 19171343; PMID 18979498; PMID 24573017; PMID 23202125; PMID 22623978; PMID 17554300; PMID 33321069;European; Multiethnic; [PMID 17554300]: 1 x 10-13; [PMID 33321069]: 5 x 10-18;0.9

Timely detection and diagnosis of heart disorders can lead to enhanced treatment options, help to prevent sudden cardiac death, and improve prognosis. This report analyzes the most relevant genes for arrhythmias, congenital heart disease, and cardiomyopathies. Analyzed gene abnormalities may cause the following syndromes: Long and short QT, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, cardiomyopathies dilated and hypertrophic, and congenital heart defects. In addition, this panel includes vascular abnormalities, such as dolichoectasia and hereditary hemorrhagic telangiectasia.

+
# GenersIDcDNA changeYour genotypeSequence ontologySIFT prediction Allele FrequencySignificanceClinVar IDOMIM
+
1DMD rs1801187 c.5234G>A T/TMISDamaging 0.513357050928 Benign 94657 302045; 310200
+
2FKTN rs34787999 c.608G>A A/AMISDamaging 0.249202580096 Benign/Likely benign 93522 253800; 611588; 611615; 613152
+
3KCNH2 rs958442820 c.2735G>A T/CMISTolerated 5.26315789474e-05 Uncertain significance 527012 527012
+
4PKD1L1 rs2686817 c.934G>T A/CMISDamaging 0.493475262581 Benign 1237805 1237805
+
5NME8 rs56128139 c.1478T>C C/TMISDamaging 0.271294673582 Benign 178811 178811
+
6NME8 rs62001869 c.1007G>A A/GMISDamaging 0.0157295398914 Benign 226853 610852
+
7NME8 rs10250905 c.622T>C C/TMISDamaging 0.736013477567 Benign 164801 164801
+
8DNAH11 rs2003417 c.7756T>C C/TMISDamaging 0.0372413741442 Benign/Likely benign 163111 163111
+
9DNAAF5 rs4720951 c.1895T>C C/TMISDamaging 0.433830778724 Benign 260930 260930
+
10DNAAF5 rs6946758 c.1784-1298C>G G/CINTDamaging 0.427423699075 Benign 1185315 1185315
+
11SYNE1 rs4407724 c.10191C>A T/TSYNDamaging 0.658192709733 Benign 130388 130388
+
12SYNE1 rs4645434 c.12180G>T A/AMISDamaging 0.580499724183 Benign 130397 610743; 612998
+
13ANK2 rs36210417 c.9854T>C C/TMISDamaging 0.00863359900073 Benign/Likely benign 190528 600919
+
14MYLK rs9840993 c.439C>T A/AMISDamaging 0.94149056791 Benign 198606 613780
+
15RAF1 rs759107333 c.1420A>G C/TMISDamaging 7.95772854596e-06 None None None
+
16TBX1 rs4819522 c.1049C>T T/TMISDamaging 0.207468145769 Benign 403525 403525
+
17GATA5 rs113068438 c.8A>G C/TMISDamaging 0.00586321781789 Benign 180366 180366
+
18TTN rs10497520 c.3601A>G C/CMISDamaging 0.688710066049 Benign 46973 600334; 604145; 608807; 611705; 603689
+
19TTN rs2291311 c.9781G>A T/TMISDamaging 0.844463342901 Benign 47692 600334; 604145; 608807; 611705; 603689
+
20DNAAF3 rs2365725 c.875A>G C/TMISDamaging 0.171971791255 Benign/Likely benign 257676 606763
+
21RYR1 rs2071089 c.9186A>G G/ASYNDamaging 0.322394110213 Benign 93306 93306
+
22NOTCH3 rs11670799 c.1487C>T A/GMISDamaging 0.011983974782 Benign/Likely benign 256120 125310
+
23NOTCH3 rs4809029 c.5913+28T>G C/CINTDamaging 0.868945990553 Benign 811011 811011
+
24DTNA rs9944927 c.*2593G>A A/GUT3Damaging 0.219157079015 Benign 137181 137181
+
25CCDC40 rs7207166 c.2832+381G>A A/AINTDamaging 0.711252785343 Benign 1283901 1283901
+
26COL1A1 rs781614679 c.3754C>T A/GMISDamaging 1.19636305631e-05 Uncertain significance 1037654 1037654
+
27JUP rs41283425 c.425G>A T/CMISDamaging 0.0438894050371 Benign/Likely benign 45851 601214; 611528
+
28GAS8 rs17178299 c.776G>A A/GMISDamaging 0.0526985397651 Benign 402892 402892
+
29MYH11 rs113964173 c.5676G>C G/CMISDamaging 0.00501641478463 Benign/Likely benign 138358 132900
+
30ALPK3 rs187316 c.4259T>C C/TMISDamaging 0.226143503793 Benign 384691 384691
+
31DNAAF4 rs600753 c.572A>G C/TMISDamaging 0.554209658117 Benign 262315 262315
+
32SYNE2 rs142660236 c.15794T>C C/TMISDamaging 0.0137591284823 Benign 130481 612999
+
33SYNE2 rs8010699 c.9926A>G G/GMISDamaging 0.804419189222 Benign 130521 612999
+
34SYNE2 rs8010911 c.9757G>C C/CMISDamaging 0.803822390229 Benign 130520 612999
+
35SYNE2 rs4027402 c.6851C>T T/TMISDamaging 0.809269092335 Benign 130504 612999
+
36SYNE2 rs4902264 c.5906T>C C/TMISDamaging 0.807647922039 Benign 130501 612999
+
37SOS2 rs3736760 c.2057+38C>T A/GINTDamaging 0.762008389107 Benign 1266724 1266724
+
38DNAAF2 rs2985684 c.186G>C G/GMISDamaging 0.64203724391 Benign 95893 612518
+
39MMP3 rs679620 c.133A>G C/TMISDamaging 0.578682343782 Benign 403098 403098
+
40MYBPC3 rs3729986 c.472G>A T/CMISDamaging 0.0662396894711 Benign 42758 615396; 115197
+
41BAG3 rs2234962 c.451T>C C/TMISDamaging 0.170283253861 Benign/Likely benign 44783 612954; 613881
+
42MYPN rs7079481 c.3403C>A A/AMISDamaging 0.430328419891 Benign 31800 615248
+
43CACNB2 rs58225473 c.1965T>G G/TMISDamaging 0.137294962562 Benign 136649 611876
+
44CPT2 rs1799822 c.1939A>G G/AMISDamaging 0.162231592375 Benign 92433 600649; 608836
+
45SELENON rs2294228 c.1506C>A A/AMISDamaging 0.771142168881 Benign 95959 602771

Lipid metabolism plays an important role in the development of heart disease, and this risk increases with age. Cholesterol is a type of lipid that is carried in the blood by lipoproteins, including low-density lipoprotein (LDL) and high-density lipoprotein (HDL). LDL is often referred to as "bad" cholesterol, as high levels of LDL are associated with an increased risk of CAD. HDL, on the other hand, is often referred to as "good" cholesterol, as it helps to remove cholesterol from the bloodstream and may have a protective effect against CAD. As we age, our lipid metabolism tends to change. For example, LDL cholesterol levels tend to increase, while HDL cholesterol levels tend to decrease. This can increase the risk of CAD and other heart diseases.

Genetics plays an important role in lipid metabolism and the development of heart disease. Genes control the production, transport, and metabolism of cholesterol and other lipids.

This report contains data of the PRS of Coronary atherosclerosis development (PGS001839), and the list with genes, associated with an increased risk of CAD. It's important to note, however, that genetics is just one of many factors that contribute to lipid metabolism and the development of heart disease. Lifestyle factors, such as diet and physical activity, are also important contributors to lipid metabolism and the development of heart disease, and they can modify the effects of genetic factors.

How to read the result?

PRS is represented as a percentile within a given population. For example, you have the 70th percentile, which means your personal genetic risk of the disease development is higher than 70 out of every 100 people in a chosen population.

So percentile >50 shows an increased risk, <50 - decreased one.

TitleCoronary atherosclerosis (PGS001839)
Sum0.5174837117616977
Count/total15921/25425
Average1.625160830857665e-05
Percentile3%

+
# RSIDGeneRisk AlleleGenotypePubmed ID PopulationP-ValueWeight
+
1 rs429358 APOE C CT[PMID 20429872]; [PMID 34887591]; [PMID: 34887591];European; Asian; African; 6,00E-256-1.5
+
2 rs268 LPL G GG[PMID 22399527]; [PMID: 20429872]; [PMID 16741292]; [PMID 16651467];European; 2,00E-12-1.0
+
3 rs12740374 CELSR2 G TT[PMID: 18262040]; [PMID: 25350695]; [PMID: 28577571];European; African; 2,00E-26-0.8
+
4 rs12740374 CELSR2 G TT[PMID: 18262040]; [PMID: 25350695]; [PMID: 28577571];European; African; 4,00E-202-0.8
+
5 rs7679 PCIF1 C CC[PMID: 19060906]; [PMID: 19965587];European; 7,00E-11-0.8
+
6 rs1800961 HNF4A T TT[PMID: 24097068]; [PMID: 18660489]; [PMID: 30698716];European; 2,00E-34-0.8
+
7 rs708272 CETP G GG[PMID 18560005]; [PMID 20031564]; [PMID: 27608031]; [PMID: 31739638]; [PMID: 34503513];European; Han Chinese; Asian; Western Siberia; 3,00E-11-0.5
+
8 rs6756629 ABCG8, ABCG5 G GG[PMID: 20832063]; [PMID:19060911];European; 3,00E-06-0.5
+
9 rs328 LPL G GC[PMID: 18193044]; [PMID: 30944368]; [PMID: 19148283];European; African 2,00E-28-0.4
+
10 rs2967605 RAB11B T TT[PMID: 29507422];European; 8,00E-09-0.3

Thrombophilia is a condition in which an individual has an increased tendency to develop blood clots. This can be caused by genetic or acquired factors, and the risk of developing thrombophilia increases with age. Thrombophilia risk has a strong genetic component, as certain genetic mutations can increase the risk of developing blood clots. The most common genetic mutations associated with thrombophilia are mutations in the genes that control the production and function of clotting factors.

This report contains data of blood clot or deep vein thrombosis (PGS000931), and the list with genes, associated with an increased risk of thrombophilia.

However, it's important to note that having a genetic mutation does not necessarily mean that an individual will develop thrombophilia. Other factors, such as lifestyle factors and medical conditions, can also contribute to the development of thrombophilia.

How to read the result?

PRS is represented as a percentile within a given population. For example, you have the 70th percentile, which means your personal genetic risk of the disease development is higher than 70 out of every 100 people in a chosen population.

So percentile >50 shows an increased risk, <50 - decreased one.

TitleBlood clot or deep vein thrombosis (PGS000931)
Sum0.27972496455000007
Count/total329/512
Average0.0004251139278875381
Percentile97%

+
# RSIDGeneRisk AlleleGenotypePubmed ID PopulationP-ValueWeight
+
1 rs1801133 MTHFR A AG[PMID: 30466296]; [PMID: 20031578]; [PMID: 34707639];European; East Asians; West Asians; [PMID: 20031578]: 8 x 10-35; [PMID: 34707639]: 4 x 10-104;-1.3
+
2 rs1799889 SERPINE G GG[PMID 9700201]; [PMID 16424345]; [PMID 25020710]; [PMID: 17896948];None None-1.3
+
3 rs1800790 FGB A AG [PMID 29235504]; [PMID: 31354890]None None-0.3
+
4 rs8176719 ABO C C-[PMID: 22672568]; [PMID 21463476];European [PMID: 22672568]: 6 x 10-12-0.3
+
5 rs2519093 ABO T CC[PMID: 21463476]; [PMID: 33512453]; [PMID: 31420334]European; African American; [PMID: 31420334]: 4 x 10-1690.0
+
6 rs6025 F5 T TT[PMID 28373160]; [PMID 23900608]; [PMID 14996674]; [PMID 10666427]; [PMID 10477778]; European; African American; [PMID: 31676865]: 1 x 10-300; 0.0
+
7 rs1799963 F2 A AA[PMID 23900608]; [PMID 19404532];[PMID 22784820];European [PMID: 26908601]:1 x 10-240.0
+
8 rs5918 ITGB3 C CC[PMID 8598867]; [PMID 9700201]; [PMID 11723016]; [PMID 19786296]None None0.0
+
9 rs2036914 F11 C CC[PMID: 19583818]; [PMID: 31420334]; [PMID 21232005]; [PMID 23150947]; [PMID: 25091233]European; African Americans [PMID 31420334]: 2 x 10-540.0